Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934022 · ClinicalTrials.gov registry record · NA
Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
A NA study, sponsored by Southern California Institute for Research and Education.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02934022 is a NA study that has completed, run by Southern California Institute for Research and Education. The registered enrollment target is 25 participants.
The verdict
NCT02934022, a NA study, has completed, sponsored by Southern California Institute for Research and Education.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patients may result in an increase in their CD4 counts. As the patient would be continuing their prior regimen, they will likely continue with full control of viral replication.
Interventions
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02934022
The ClinicalTrials.gov registry entry for NCT02934022 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern California Institute for Research and Education, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maraviroc is the first listed.
NCT02934022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02934022 about?
NCT02934022 is a clinical study titled "Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients". Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patie...
What is the current status of trial NCT02934022?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2012-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02934022?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02934022?
This trial is sponsored by Southern California Institute for Research and Education, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.